157 related articles for article (PubMed ID: 38671015)
1. Integrated aerobic exercise with LDE-docetaxel treatment: a novel approach to combat prostate cancer progression.
Veras ASC; Batista VRG; Correia RR; de Almeida Tavares ME; Rubira RJG; Tavares ER; Giometti IC; Maranhão RC; Teixeira GR
Sci Rep; 2024 Apr; 14(1):9626. PubMed ID: 38671015
[TBL] [Abstract][Full Text] [Related]
2. Lipid core nanoparticles as vehicle for docetaxel reduces atherosclerotic lesion, inflammation, cell death and proliferation in an atherosclerosis rabbit model.
Meneghini BC; Tavares ER; Guido MC; Tavoni TM; Stefani HA; Kalil-Filho R; Maranhão RC
Vascul Pharmacol; 2019 Apr; 115():46-54. PubMed ID: 30797043
[TBL] [Abstract][Full Text] [Related]
3. PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer.
Nagesh PKB; Johnson NR; Boya VKN; Chowdhury P; Othman SF; Khalilzad-Sharghi V; Hafeez BB; Ganju A; Khan S; Behrman SW; Zafar N; Chauhan SC; Jaggi M; Yallapu MM
Colloids Surf B Biointerfaces; 2016 Aug; 144():8-20. PubMed ID: 27058278
[TBL] [Abstract][Full Text] [Related]
4. TGF-β causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization.
Li Y; Zhang B; Xiang L; Xia S; Kucuk O; Deng X; Boise LH; Dong JT
Theranostics; 2020; 10(17):7656-7670. PubMed ID: 32685011
[TBL] [Abstract][Full Text] [Related]
5. Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition.
Tamaki H; Harashima N; Hiraki M; Arichi N; Nishimura N; Shiina H; Naora K; Harada M
Oncotarget; 2014 Nov; 5(22):11399-412. PubMed ID: 25333266
[TBL] [Abstract][Full Text] [Related]
6. ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer.
Wang Z; Zhang X; Li W; Su Q; Huang Z; Zhang X; Chen H; Mo C; Huang B; Ou W; Chen J; Zhao G; Chen L; Shao L
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34301812
[TBL] [Abstract][Full Text] [Related]
7. Cross-Linked Polyphenol-Based Drug Nano-Self-Assemblies Engineered to Blockade Prostate Cancer Senescence.
Nagesh PKB; Chowdhury P; Hatami E; Kumari S; Kashyap VK; Tripathi MK; Wagh S; Meibohm B; Chauhan SC; Jaggi M; Yallapu MM
ACS Appl Mater Interfaces; 2019 Oct; 11(42):38537-38554. PubMed ID: 31553876
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer cells hyper-activate CXCR6 signaling by cleaving CXCL16 to overcome effect of docetaxel.
Kapur N; Mir H; Sonpavde GP; Jain S; Bae S; Lillard JW; Singh S
Cancer Lett; 2019 Jul; 454():1-13. PubMed ID: 30974114
[TBL] [Abstract][Full Text] [Related]
9. Reversal of drug resistance by planetary ball milled (PBM) nanoparticle loaded with resveratrol and docetaxel in prostate cancer.
Singh SK; Lillard JW; Singh R
Cancer Lett; 2018 Jul; 427():49-62. PubMed ID: 29678549
[TBL] [Abstract][Full Text] [Related]
10. Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo.
Yan J; Wang Y; Zhang X; Liu S; Tian C; Wang H
Drug Deliv; 2016 Jun; 23(5):1757-62. PubMed ID: 26203689
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel-loaded solid lipid nanoparticles prevent tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells.
da Rocha MCO; da Silva PB; Radicchi MA; Andrade BYG; de Oliveira JV; Venus T; Merker C; Estrela-Lopis I; Longo JPF; Báo SN
J Nanobiotechnology; 2020 Mar; 18(1):43. PubMed ID: 32164731
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
Pilling A; Kim SH; Hwang C
Prostate; 2022 Feb; 82(2):182-192. PubMed ID: 34672379
[TBL] [Abstract][Full Text] [Related]
13. Incorporation of docetaxel and thymoquinone in borage nanoemulsion potentiates their antineoplastic activity in breast cancer cells.
Alkhatib MH; Bawadud RS; Gashlan HM
Sci Rep; 2020 Oct; 10(1):18124. PubMed ID: 33093596
[TBL] [Abstract][Full Text] [Related]
14. Co-delivery of docetaxel and curcumin prodrug via dual-targeted nanoparticles with synergistic antitumor activity against prostate cancer.
Yan J; Wang Y; Jia Y; Liu S; Tian C; Pan W; Liu X; Wang H
Biomed Pharmacother; 2017 Apr; 88():374-383. PubMed ID: 28122302
[TBL] [Abstract][Full Text] [Related]
15. Long noncoding RNA MALAT1 enhances the docetaxel resistance of prostate cancer cells via miR-145-5p-mediated regulation of AKAP12.
Xue D; Lu H; Xu HY; Zhou CX; He XZ
J Cell Mol Med; 2018 Jun; 22(6):3223-3237. PubMed ID: 29633510
[TBL] [Abstract][Full Text] [Related]
16. Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy.
Sundaram S; Durairaj C; Kadam R; Kompella UB
Mol Cancer Ther; 2009 Jun; 8(6):1655-65. PubMed ID: 19509261
[TBL] [Abstract][Full Text] [Related]
17. Prostate Cancer Therapy Using Docetaxel and Formononetin Combination: Hyaluronic Acid and Epidermal Growth Factor Receptor Targeted Peptide Dual Ligands Modified Binary Nanoparticles to Facilitate the in vivo Anti-Tumor Activity.
Dong Z; Wang Y; Guo J; Tian C; Pan W; Wang H; Yan J
Drug Des Devel Ther; 2022; 16():2683-2693. PubMed ID: 35983428
[TBL] [Abstract][Full Text] [Related]
18. Induction of Endoplasmic Reticulum Stress-Mediated Apoptosis by Aminosteroid RM-581 Efficiently Blocks the Growth of PC-3 Cancer Cells and Tumors Resistant or Not to Docetaxel.
Maltais R; Roy J; Perreault M; Sato S; Lévesque JC; Poirier D
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681843
[TBL] [Abstract][Full Text] [Related]
19. [Expression of AXL enhances docetaxel-resistance of prostate cancer cells].
Lin JZ; Zhu JG; Wu HF; Li JM; DE W; Wang ZJ
Zhonghua Nan Ke Xue; 2017 Apr; 23(4):302-308. PubMed ID: 29714413
[TBL] [Abstract][Full Text] [Related]
20. Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells.
Ishii K; Matsuoka I; Kajiwara S; Sasaki T; Miki M; Kato M; Kanda H; Arima K; Shiraishi T; Sugimura Y
J Cancer Res Clin Oncol; 2018 Jan; 144(1):89-98. PubMed ID: 29098395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]